Oculis secures EMA PRIME status for optic neuritis treatment Privosegtor
Oculis (NASDAQ:OCS) announced on March 31, 2026, that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation to Privosegtor for the treatment of optic neuritis.











_1371905_640x360_2494366275754-640x360.webp&w=3840&q=75)